Afatinib Plus Bevacizumab After Acquired Resistance to EGFR-TKI in EGFR-mutant NSCLC

Phase 2

• Conditions: on-small cell lung cancer

• Registration Number: JPRN-UMIN000014710
• Lead Sponsor: Foundation for Biomedical Research and Innovation

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-08-01
• Study Completion: 2017-12-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

Not provided

Exclusion Criteria

1)Obvious interstitial pneumonia or pulmonary fibrosis by chest CT 2)History of severe allergic reaction 3)Complications such as severe infection or severe comobidities 4)Uncontrolled pleural or pericardial effusion 5)Clinically significant heart disease 6)Uncontrolled hypertension 7)Uncontrolled diabate 8)Active multiple cancer 9)Squamous histology 10)Aparent invasion of main vessels 11)Clinically significant phycological problem 12)History of significant hemoptysis or respiratory bleeding 13)History of GI perfolation 14)non-curable bone fracture or severe injury 15)Planning surgery 16)Significant lung cavitation 17)Bleeding tendency 18)Uncontrolled thromboembolism 19)Prior therapy of EGFR-TKI+bevacizumab 20)History of Afatinib administration 21)Pregnancy 22)Inadequate patients whom physitians considered

Study & Design

• Study Type: Interventional,observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Response rate

Secondary Outcome Measures

Name	Time	Method
Progression-free survival Disease control rate Overall survival Safety